<DOC>
	<DOCNO>NCT02166151</DOCNO>
	<brief_summary>The study design assess efficacy safety monthly injection Omalizumab 150 mg 3 consecutive month , patient chronic idiopathic urticaria , unresponsive convetional therapy antihistamins oral corticosteroid .</brief_summary>
	<brief_title>Efficacy Safety Omalizumab Chronic Idiopathic Urticaria</brief_title>
	<detailed_description />
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>diagnosis chronic idiopathic urticaria 3 month failure treatment least 2 antihistamins systemic corticosteroid cyclosporin physical cholinergic urticaria past treatment Omalizumab nprevious year parasitic infection malignancy last 5 year know sensitivity Omalizumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>